ReviewDrugs2009
Strategies to control trachoma.
Review in Drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- The impact of climatic risk factors on the prevalence, distribution, and severity of acute and chronic trachoma.PLoS neglected tropical diseases · 2013Pooled it
- The added value of water, sanitation, and hygiene interventions to mass drug administration for reducing the prevalence of trachoma: a systematic review examining.Journal of environmental and public health · 2013Pooled it
- Prevalence of nasopharyngealThe Lancet. Microbe · 2022Trial
- Determinants of Low Coverage of the Free Surgical Care Programme for Trachomatous Trichiasis in Rural Guinea in 2022.Tropical medicine and infectious disease · 2024Article
- The 2023 Doyne Lecture-a cornea care system: evolution.Eye (London, England) · 2024Article
- Trachoma control: the SAFE strategy.International journal of ophthalmology · 2018Article
- Article
- Trachoma: Past, present and future.Journal of current ophthalmology · 2016Review
- Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania.Emerging infectious diseases · 2014Article
- Prevalence of trachoma in the north region of Cameroon: results of a survey in 15 health districts.PLoS neglected tropical diseases · 2014Article
- Evidence for integrating eye health into primary health care in Africa: a health systems strengthening approach.BMC health services research · 2013Review
- Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: identifying best practices to roll out programs at national scale.The American journal of tropical medicine and hygiene · 2012Article
- Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis.Drugs · 2012Review
- Prevalence of trachoma in unity state, South Sudan: results from a large-scale population-based survey and potential implications for further surveys.PLoS neglected tropical diseases · 2012Article
- Control of neglected tropical diseases needs a long-term commitment.BMC medicine · 2010Review
- Trachoma rapid assessments in Unity and Northern Bahr-el-Ghazal States, Southern Sudan.PloS one · 2010Article
- Understanding the role of aldose reductase in ocular inflammation.Current molecular medicine · 2010Review
- A Community-based Eye Care Intervention in Southern Egypt: Impact on Trachomatous Trichiasis Surgical Coverage.Middle East African journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trachoma is a significant public health problem that is endemic in 57 countries, affecting 40.6 million people and contributing to 4% of the global burden of blindness. Repeated episodes of infection from Chlamydia trachomatis lead to long-term inflammation, scarring of the tarsal conjunctiva and distortion of the upper eyelid with in-turning of eyelashes that abrade the surface of the globe. This constant abrasion, in turn, can cause irreversible corneal opacity and blindness. The Alliance for the Global Elimination of Trachoma by 2020 (GET2020) has adopted the SAFE (Surgery, Antibiotics, Facial cleanliness and Environmental improvement) strategy as the main action against trachoma. Trichiasis surgery reduces the risk of blindness by reversing the in-turning of eyelashes and also improves the quality of life from non-visual symptoms. However, future efforts need to aim at increasing accessibility to surgery and improving acceptance. Antibacterials are required to reduce the burden of infection. Oral azithromycin is as close to the perfect antibacterial as we will get for mass distribution: it is safe, requires only a single oral dose, treatment is usually repeated every 6-12 months, resistance is not seen as a problem, and cost is not a limiting factor with a large donation programme and newer generic versions of the drug. Future focus should be on the details of antibacterial distribution such as coverage, frequency of distribution and target population. The promotion of facial cleanliness through education may be the key to trachoma elimination as it will stop the frequent exchange of infected ocular secretions and thus reduce the transmission of infection. However, innovative methods are required to translate health education and promotion activities into sustainable changes in hygiene behaviour. Environmental improvements should focus on the barriers to achieving facial cleanliness and cost-effective means need to be identified. There are a number of countries already eligible for certification of trachoma elimination and if current momentum continues, blinding trachoma can be eliminated by the year 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.